Sign in
Taking peopleNo phase

Diagnostic Yield of Post PRandial Esophageal High Resolution Impedance Manometry in Patients With Gastro-Esophageal Reflux Disease Symptoms Resistant to Proton Pump Inhibitor Therapy

Key facts

Who runs it
Hospices Civils de Lyon
Where
France7 sites in 1 countryChoose a country to see its sites
Trial code
Status
Recruiting
People taking part
330 people, planned
Started
3 May 2021
Expected to end
3 May 2027
Type of study
Interventional
Treatments tested
  • Upper gastrointestinal (GI) endoscopy
  • Wireless pH monitoring
  • Post prandial esophageal High Resolution Impedance Manometry
  • pH-impedance monitoring
Record updated
26 June 2024

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 16 criteriaShow less

Who can take part

  • Patient older than 18 years
  • Typical symptoms of GERD (heartburn, regurgitation) at least twice a week despite PPI therapy for at least one month
  • Reflux Disease Questionnaire (RDQ) score off PPI > 3
  • Subject with health insurance

Who cannot take part

  • Previous esophago-gastric surgery,
  • Previous history of developing esophageal or gastric tumor, esophageal stricture, or esophageal varices
  • Contraindications to the wireless capsule pH-monitoring: pacemakers, implantable cardiac defibrillator,
  • Contraindications to HRIM: inability to tolerate nasal intubation, significant bleeding disorders for which nasal intubation is contraindicated, known esophageal obstruction is preventing the passage of the HRIM probe
  • Intolerance or allergy to one component of the test meal,
  • Intolerance or allergy to PPI,
  • Pregnancy (assessment at V0)
  • Contraindication to general anesthesia,
  • Inability to give consent,
  • Mentally unbalanced patients, under supervision or guardianship
  • Decline to participate in the study,
  • Participation in another study at the same time

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Gastro-esophageal reflux disease (GERD) is defined as the reflux of gastric content into the esophagus that causes troublesome symptoms or complications. Nine to 30% of the population suffers from GERD-suggestive symptoms (heartburn, regurgitation, chest pain, chronic couch, sore throat). In the absence of warning signs, proton pump inhibitors (PPI) are prescribed as first-line treatment. However, 20 to 60% of patients are unsatisfied because of persistent symptoms when taking PPI. Causes of persistent symptoms are: erroneous diagnosis of GERD (up to 50% of PPI non-responders), rumination syndrome, excessive weakly acid reflux on PPI due to defective esophago-gastric junction or an excessive number of transient lower esophageal sphincter relaxations (main mechanism of GERD), poor acid secretion inhibition on PPI, and non-compliance to therapy. Complementary examinations are indicated to explain persistent GERD symptoms. Upper gastro-intestinal endoscopy is performed first to rule out an esophageal tumor and to identify erosive esophagitis, a specific sign of GERD. However, it is normal in up to 70% of symptomatic GERD patients. Direct detection of reflux episodes is then requested to confirm GERD. The gold standard for reflux detection is the ambulatory measurement of esophageal pH for 24 to 96 hours using a catheter (catheter-based pH-monitoring) or a capsule clipped into the esophagus (wireless pH-monitoring). Reflux episodes are defined as an esophageal pH < 4. Another method of reflux detection is based on liquid and gas detection in the esophagus using pH-impedance monitoring. Recently the combination of impedance and esophageal pressure monitoring, called esophageal high resolution impedance manometry (HRIM) was introduced to simultaneously identify reflux episodes and their mechanisms. It has several advantages over esophageal pH measurement: shorter recording duration (1 or 2 hours post prandial) and identification of reflux mechanisms that might guide the choice of the best therapeutic option.

Read full original descriptionShow less

Hypothesis: The 1-hour post prandial esophageal HRIM might be useful to diagnose GERD.

The group in the trial

  • Patients with persistent GERDTreatment being tested

    Patients with persistent GERD suggestive symptoms despite PPI therapy. All the patients will undergo an upper gastrointestinal (GI) endoscopy, a wireless pH monitoring and a post prandial esophageal High Resolution Impedance Manometry (HRIM). Optional: 24-h pH-impedance monitoring on PPI

    Treatment: Upper gastrointestinal (GI) endoscopy, Wireless pH monitoring, Post prandial esophageal High Resolution Impedance Manometry, and pH-impedance monitoring

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Record updated
26 June 2024